TIL Q4 2024 Earnings — Instil Bio, Inc. Revenue & Financial Results | Market Cap Arena

TILInstil Bio, Inc.

$62M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$741,000

Operating Income

-$11M

Net Income

-$12M

EPS (Diluted)

$-1.82

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$264M

Total Liabilities

$94M

Stockholders' Equity

$169M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$741,000	-$1M	+28.5%
Operating Income	-$11M	-$13M	+10.8%
Net Income	-$12M	-$13M	+8.0%